Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1399

NGM438-hIgG1

Home » Antibodies » NGM438-hIgG1

Background of NGM438-hIgG1

LAIR1 is a hematopoietic lineage-restricted collagen receptor reported to regulate diverse responses across both innate and adaptive immune cell types, including activation, differentiation, and antigen recognition. NGM438, a novel humanized LAIR1 antagonist monoclonal antibody, elicits myeloid inflammation and allogeneic T cell responses by binding to LAIR1 and blocking collagen engagement.

Specifications

Catalog Number:
KB-1399
Antibody Name:
NGM438-hIgG1
Isotype:
Human IgG1,kappa
FC Muations:
Target:
LAIR-1
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Preclinical Development of NGM438, a Novel Anti-LAIR1 Antagonist Monoclonal Antibody for the Treatment of Collagen-Rich Solid Tumors-AACR 2022 Abstract # 7571
  2. Rodriguez BL, Huang J, Gibson L, Fradette JJ, Chen HH, Koyano K, Cortez C, Li B, Ho C, Ashique AM, Lin VY, Crawley S, Roda JM, Chen P, Fan B, Kim J, Sissons J, Sitrin J, Kaplan DD, Gibbons DL, Rivera LB. Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors. Mol Cancer Ther. 2024 Aug 1;23(8):1144-1158.